Skip to main content
2025 DC/CSEM Professional Conference Main banner
On-Demand

Plenary Session

PS1 - The Future of Diabetes Therapies: GLP-1s and Beyond

Thursday, November 27, 2025
08:00 - 09:00 Toronto
Location: Constitution Hall

    Speaker(s)

  • Marc Y. Donath, Professor/Endocrinologist (he/him/his)

    Medical Director
    Integrated Centre of Excellence in Metabolic Health
    Montréal, Quebec, Canada

    Disclosure(s): Lilly: Consultant (Terminated, May 29, 2025); Novo Nordisk: Consultant (Terminated, February 28, 2025); Olatec: Advisory Board (Ongoing)

    • Moderator(s)

  • Julie A. Lovshin, MD, PhD, FRCPC (she/her/hers)

    Endocrinologist & Clinical Investigator
    Sunnybrook Hospital, University of Toronto
    University of Toronto
    Toronto, Ontario, Canada

    Disclosure(s): Boehringer Ingelheim: Consultant (Ongoing); Canadian Cardiovascular Society: Speaker/Honoraria (Terminated, November 30, 2024); CPD Network Association: Speaker/Honoraria (Ongoing); Diabetes Canada: Speaker/Honoraria (Ongoing); Eli Lilly Canada: Speaker/Honoraria (Ongoing); Novo Nordisk Canada: Speaker/Honoraria (Ongoing); NovoNordisk: Speaker/Honoraria (Ongoing)

Disclosure(s):
Marc Y. Donath, Professor/Endocrinologist: Lilly: Consultant (Terminated, May 29, 2025); Novo Nordisk: Consultant (Terminated, February 28, 2025); Olatec: Advisory Board (Ongoing)
Julie A. Lovshin, MD, PhD, FRCPC: Boehringer Ingelheim: Consultant (Ongoing); Canadian Cardiovascular Society: Speaker/Honoraria (Terminated, November 30, 2024); CPD Network Association: Speaker/Honoraria (Ongoing); Diabetes Canada: Speaker/Honoraria (Ongoing); Eli Lilly Canada: Speaker/Honoraria (Ongoing); Novo Nordisk Canada: Speaker/Honoraria (Ongoing); NovoNordisk: Speaker/Honoraria (Ongoing)
Learning Objectives: This session will address:
1. Appraise the current state-of-the-art of GLP-1 and GIP Receptor agonists, including basic and clinical science and their therapeutic use for weight loss and diabetes.
2. Highlight the upcoming incretin-based medications, including dual and tri-agonist therapies in clinical development.
3. Explore the synergistic potential of GLP-1 and GIP receptor agonists in combination with other drugs to optimize the clinical benefits for obesity and diabetes.